Navigation Links
Abbott Announces Positive Nine-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

improved radial strength, which is intended to maintain vessel expansion so blood can flow through.

"Not only is the ABSORB trial beginning to show that bioabsorbable technology, when applied to coronary stents, can work -- it can also provides a foundation for future interventional medical innovation," said John M. Capek, Ph.D., senior vice president, Abbott Vascular. "Five years ago, the technology and 'know-how' to make a fully functioning bioabsorbable drug eluting stent didn't exist, but every success in the ABSORB trial brings us one step closer to providing this important new treatment option to physicians for their patients."

About the ABSORB Clinical Trial

The ABSORB trial is a prospective, non-randomized (open label) study designed to enroll up to 60 patients in Belgium, Denmark, France, New Zealand, Poland and The Netherlands. Key endpoints of the study include assessments of safety; MACE and stent thrombosis (blood clot formation) rates at 30, 180 and 270 days, with an annual follow-up for up to five years, and successful deployment of the bioabsorbable drug eluting stent. Other key endpoints of the study include follow-up measurements assessed by X-ray angiography, intravascular ultrasound (IVUS), and state-of-the-art imaging modalities at 180 days and two years.

In March, six-month results from the first 30 patients in the ABSORB trial were presented at the of Cardiology conference, demonstrating no stent thrombosis and a low (3.3 percent, one patient) of Major Adverse Cardiac Events (MACE), such as heart attack or repeat interventional medical treatment.

For images of Abbott's investigational bioabsorbable stent and other information, please visit the company's online newsroom at http://www.abbottvascular.com/presskit.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses.
'"/>




Page: 1 2 3

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
3. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
4. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
5. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/7/2015)... , July 7, 2015 A power morcellator ... has been settled for an undisclosed amount, Bernstein Liebhard ... filed in March 2014 in the U.S. District Court, ... behalf of a widower whose wife had died in ... a hysterectomy that involved the use of a power ...
(Date:7/7/2015)... According to a new market research ... (Consumables, Instrument), Application (Aerobic, Anaerobic, Yeast/ Fungi) & End User ... to 2019", published by MarketsandMarkets, The global Blood Culture Tests ... $2,750.2 Million in 2014 at a CAGR of 7.2% from ... ma rket data T ables and ...
(Date:7/7/2015)... 7, 2015 C,est ... annonce l,acquisition de 20% du Groupe TRB, ... spécialisée dans la fabrication de médicaments et ...      (Logo: http://photos.prnewswire.com/prnh/20150707/232398LOGO) , ... groupes chimiques et pharmaceutiques italiens, qui contrôle, ...
Breaking Medicine Technology:Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 2Lina Medical, Power Morcellator Lawsuit Plaintiff Reach Settlement in Case Scheduled for November Trial, Bernstein Liebhard LLP Reports 3Blood Culture Tests Market Worth $3,893.5 Million by 2019 2Blood Culture Tests Market Worth $3,893.5 Million by 2019 3Blood Culture Tests Market Worth $3,893.5 Million by 2019 4
... BOULDER, Colo. and MONTREAL, Jan. 9 ... Inc. (TSX: MYG) today announced,the enrollment of ... clinical trial (Trial,CL002) evaluating MGCD0103, the Companies, ... combination with,Vidaza(R) (azacitidine for injection), Pharmion,s DNA ...
... Whatever illness it is, it can make you feel ... but it is even more difficult to handle,being sick ... Diabetes Association (ADA), people with,diabetes who develop an illness ... care of their diabetes. Blood glucose levels can increase,or ...
Cached Medicine Technology:Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 2Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 3Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 4Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 5Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 6Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma 7Help! I'm Sick. How Do I Handle My Diabetes? 2
(Date:7/7/2015)... ... July 07, 2015 , ... Georgia Partnership ... in communities throughout Georgia, announces the launch of the first ambulance telemedicine program ... Hancock County, GA. The new program will not only provide more immediate patient ...
(Date:7/7/2015)... ... July 07, 2015 , ... America is blessed with people who ... A Hero program offers a special way to say “thanks.” Give them the ... $250 gift card and their place on the “Wall of Heroes.” , “We ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... motivated leaders with strong managerial expertise to oversee large healthcare operations and ... staff, providers, business partners, insurance companies, and regulators. American Sentinel University, an ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... On May ... effective immediately and permits the use of gluten-free claims for gluten free oats and ... of expanding the Gluten-Free Certification Program (GFCP) to include gluten-free oat products ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... they have been selected by the Department of Vermont Health Access to provide ... Management Information System (MMIS) and Integrated Contact Center System project. , Vermont is ...
Breaking Medicine News(10 mins):Health News:Georgia Partnership for TeleHealth prepares to Launch First Ambulance Telemedicine Solution in Georgia 2Health News:California Casualty Wants to Know: "Who Is Your Hero?" 2Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 2Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 3Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 4Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 2Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 4Health News:CSG Government Solutions Selected by the Department of Vermont Health Access to Provide Quality Assurance and Independent Verification and Validation Services 2
... April 29 Pennsylvania,s chief agriculture and ... improve national and state food safety initiatives at the ... in Harrisburg. Agriculture Secretary Dennis Wolff and Health Secretary ... in protecting the food supply and responding to outbreaks, ...
... Almost half of those in ICU had deficient levels, study ... levels are deficient in many critically ill patients, new research ... almost half of people in an intensive care unit were ... to be common in seriously ill patients," said study author ...
... April 29 Varian Medical Systems (NYSE: ... of $0.64 per diluted share in the second quarter ... operations of $0.57 per diluted share in the year-ago ... net earnings per diluted share in the quarter were ...
... SGMO ) today reported first quarter 2009 financial ... 2009, Sangamo reported a consolidated net loss of $6.8 million, ... $8.0 million, or $0.20 per share, for the same period ... cash and cash equivalents, marketable securities and interest receivable of ...
... of sleep for patients, study finds, , , WEDNESDAY, April ... treat epilepsy, nerve pain, anxiety and fibromyalgia, shows promise ... Spanish researcher reports. , Some 5 percent to 10 ... legs syndrome (RLS), a disorder that causes people to ...
... receive a scratch ticket from Uno Chicago Grill(R) worth $5, ... During the month of May, all presenting donors at ... Connecticut, along with select blood drives in Vermont and Maine, ... Chicago Grill(R)." The Boston-based restaurant group is partnering with the ...
Cached Medicine News:Health News:Pennsylvania Governor's Food Safety Council Meets to Discuss Food Supply Protection 2Health News:Critically Ill Patients Lack Vitamin D 2Health News:Critically Ill Patients Lack Vitamin D 3Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 2Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 3Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 4Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 5Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 6Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 7Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 8Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 9Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 2Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 3Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 4Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 5Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 6Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 7Health News:Common Drug Eases Restless Legs Syndrome 2Health News:Try Your Luck with 'Scratch & Win with Uno Chicago Grill'! 2Health News:Try Your Luck with 'Scratch & Win with Uno Chicago Grill'! 3
Up-tapered output compresses NA to give low NA fiber performance on high NA fiber stock....
... AAA Endovascular Graft with the H&L-B One-Shot ... for the endovascular treatment of patients with ... suitable for endovascular repair. The Zenith AAA ... an aneurysm to "seal off" the aneurysm. ...
The new series of Steris Power-lift Stirrups incorporate all of the proven clinical benefits of Allen-style booted stirrups: maximum safety for the patient, ease of setup for your staff, impressive v...
... Pneumatic lift assist stirrups are designed to travel ... -30 degrees. They lock tight wherever you release ... and adduction are done at the handle with ... side rail socket. The rotation of system was ...
Medicine Products: